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Abstract
Introduction Focal adhesion kinase (FAK) regulates multiple
cellular processes including growth, differentiation, adhesion,
motility and apoptosis. In breast carcinoma, FAK overexpression
has been linked to cancer progression but the prognostic
relevance remains unknown. In particular, with regard to lymph
node-negative breast cancer it is important to identify high-risk
patients who would benefit from further adjuvant therapy.
Methods We analyzed 162 node-negative breast cancer cases
to determine the prognostic relevance of FAK expression, and
we investigated the relationship of FAK with major associated
signaling pathways (HER2, Src, Akt and extracellular regulated
kinases) by immunohistochemistry and western blot analysis.
Results Elevated FAK expression did not predict patient
outcome, in contrast to tumor grading (P = 0.005), Akt
activation (P = 0.0383) and estrogen receptor status (P =
0.0033). Significant positive correlations were observed
between elevated FAK expression and HER2 overexpression (P
= 0.001), as well as phospho-Src Tyr-215 (P = 0.021) and
phospho-Akt (P < 0.001), but not with phospho-ERK1/2 (P =
0.108). Western blot analysis showed a significant correlation
of FAK Tyr-861 activation and HER2 overexpression (P = 0.01).
Conclusions Immunohistochemical detection of FAK
expression is of no prognostic significance in node-negative
breast cancer but provides evidence that HER2 is involved in
tumor malignancy and metastatic ability of breast cancer
through a novel signaling pathway participating FAK and Src.
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Introduction
Breast cancer is a major cause of death among women.
Adjuvant systemic therapy may considerably improve sur-
vival rates, but it is associated with severe toxic side effects.
Especially in patients with node-negative breast cancer, the
pros and cons of adjuvant systemic therapy are always crit-
ically weighted out. The identification of novel markers for
node-negative high-risk patients who would benefit from
adjuvant therapy is therefore of major importance. The aim
of the present study was to assess the prognostic rele-
vance of focal adhesion kinase (FAK) expression in node-
negative breast cancer. In addition, the present report was
designed to investigate the consequence of FAK expres-
sion on two major downstream targets (namely, Akt and
Erk1/2) and to elucidate its connection with the HER2 sig-
naling pathway.
ER = estrogen receptor; ERK = extracellular regulated kinase; FAK = focal adhesion kinase; PI3K = phosphotidylinositol-3-kinase.R194
Breast Cancer Research    Vol 7 No 2    Schmitz et al.
R195The invasion and metastasis of cancer is a complex proc-
ess including changes in cell adhesion and motility that
allow tumor cells to invade and migrate through the extra-
cellular matrix. Some of these alterations may occur at focal
adhesions, which are cell/extracellular matrix contact
points containing membrane-associated, cytoskeletal and
intracellular signaling molecules [1]. The survival of normal
epithelial cells critically depends on cell–cell and cell–
matrix contact. Without these contacts epithelial cells die
through the controlled process of apoptosis, termed
anoikis [2]. FAK is a tyrosine kinase considered a central
molecule in integrin-mediated signaling, and it is involved in
cellular motility and protection against apoptosis [3-7]. The
importance of FAK in epithelial cell biology is underlined by
the findings that epithelial cells lines expressing constitu-
tively active FAK survive in suspension and that cells
derived from FAK-/- mouse embryos exhibit reduced migra-
tion [8,9].
High levels of FAK have been found in a variety of tumors,
including head and neck carcinomas, ovarian carcinomas,
thyroid carcinomas and colon carcinomas [10-12]. Only
two studies have so far described elevated FAK expression
in human breast cancer and preinvasive lesions in contrast
to benign breast lesions in small cohorts [13,14]. The prog-
nostic value of FAK expression in breast cancer remains
unclear. Regarding other cancer types, three studies dem-
onstrated varying results in colon cancer, squamous cancer
and hepatocellular carcinoma [15-17].
Recent studies have identified HER2, a prognostic marker
for aggressiveness in breast cancer, to influence the migra-
tory behavior of breast cancer cells in vitro through a novel
signaling pathway involving phosphorylation of FAK at tyro-
sine 861 by its upstream kinase c-Src [18,19]. These find-
ings suggest that the Her-2/neu signaling pathway may
influence migration and metastasis of breast cancer cells
through activating the Src/FAK signaling pathway. There
are several downstream targets of FAK such as the Ras-
ERK signaling cascade, which is activated by extracellular,
frequently mitogenic ligands and results in increased cellu-
lar proliferation and malignancy in vitro and in vivo [20,21].
FAK also impacts on the phosphotidylinositol-3-kinase
(PI3K)/Akt-signaling pathway that plays a central role in
tumorigenesis [22,23]. In node-negative breast cancer, we
have previously shown that activated Akt is a prognostic
parameter [24].
The aim of the present study was to assess the prognostic
relevance of FAK expression in node-negative breast can-
cer. In addition, the present report was designed to investi-
gate the correlation of FAK expression with two major
downstream signaling pathways, Akt and Erk1/2, and to
elucidate its connection with the HER2 signaling pathway.
Materials and methods
Patients
This study comprised 162 female breast cancer patients
(mean age, 59 years) from the Department of Gynecology,
University of Essen-Duisburg, Germany, who underwent
surgery and further adjuvant therapy between 1989 and
1996. Complete clinical records and follow-up information
were available in all cases. The negative lymph node status
was confirmed by axillary dissection. All surgical material
was fixed in 4% formalin and routinely processed. The
tumors were classified according to the pTNM system
(sixth edition) and were graded according to Elston and
Ellis [25]. Twenty-seven of the 162 patients died during fol-
low-up, the cause of death being unknown in two cases.
Altogether 19 patients died of breast cancer, and six
patients were excluded from survival analysis having died
from either benign or other cancer diseases. Statistical
analysis was based on a mean follow-up period of 7.48
years. Table 1 summarizes the clinicopathological parame-
ters of this study.
Immunohistochemistry
The primary antibodies used in this study are presented in
Table 2. Immunohistochemistry was performed on paraffin
sections 5 µm thick. The alkaline phosphatase anti-alkaline
phosphatase method was used for antibody demonstra-
tion. Antigen retrieval was carried out with 0.01 M citrate
buffer at pH 6.1 for 20 min (both phospho-Akt antibodies),
for 40 min (phospho-ERK1/2) and for 20 min (FAK, phos-
pho-Src Tyr-215 and phospho-Src Tyr-416) in a hot water
bath (95°C). Antibodies were incubated overnight in a
humidified chamber at 4°C. Positive controls were included
in each staining series. No significant staining was
observed in the negative controls using mouse immu-
noglobin replacing the primary antibody. The DAKO Her-
ceptTest™ (DakoCytomation, Glostrup, Denmark) and a
HER2/ErbB2 polyclonal antibody at a 1:50 dilution (rabbit
polyclonal antibody; Cell Signaling Technology, Beverly,
MA, USA) were used for the detection of HER2 protein
expression. The estrogen receptor (ER) status of the
tumors was determined using a monoclonal anti-human
antibody as previously described [24].
Evaluation of immunostaining
FAK immunostaining
The constant positive staining of smooth muscle cells of
tumor vessels served as the positive internal control as pre-
viously described [26]. If more than 20% of carcinoma cells
in a given specimen were stained more intensely than
smooth muscle cells, the sample was classified as strong
FAK overexpression (3+). In the case of equal FAK immu-
nostaining compared with that of vascular smooth muscle
cells, the sample was classified as intermediate expression
(2+). When FAK immunostaining was weaker than that of
the internal control, the tumor was classified as low FAK
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classified as negative (0). For statistical analysis, negative
(0), intermediate (1+ and 2+) and strong (3+) groups were
created.
Phospho-Akt and phospho-ERK1/2 immunostaining
The number of positive immunoreactive tumor nuclei was
counted within 300 cells at the invasive tumor front, and is
expressed as a percentage. Cytoplasmatic phospho-Akt
staining was noticed but was not part of the scoring sys-
tem. Tumor cells with easily detectable specific phospho-
ERK1/2 immunostaining, independent of the amount of
stained cells, were scored as strongly positive (2+).
Tumors exhibiting a detectable but faint immunostaining
were scored as weak (1+), whereas tumors with a minimal,
hardly detectable or missing staining pattern were classi-
fied as phospho-ERK1/2-negative (0).
Phospho-Src Tyr-215 and phospho-Src Tyr-416 
immunostaining
Most tumor samples showed a membranous staining with
varying intensity. Four samples revealed a strong cytoplas-
Table 1
Clinicopathological data and focal adhesion kinase expression in 162 node-negative breast cancers
Focal adhesion kinase expression P value*
Negative Strong Intermediate
Total adenocarcinoma 13 (8%) 30 (18.5%) 119 (73.5%)
Tumor type Not significant
Invasive ductal 5 (4.1%) 27 (22.5%) 88 (72.7%)
Invasive lobular 3 (13%) 2 (8.7%) 18 (78.3%)
Mucinous 5 (62.5%) / 3 (37.5%)
Tubulo/tubulo-lobular / / 5 (100%)
Others / 1 (16.7%) 5 (88.3%)
Histological grade P = 0.038*
Well differentiated 4 (11.4%) 3 (8.6%) 28 (80%)
Moderately differentiated 6 (7%) 13 (15.1%) 67 (77.9%)
Poorly differentiated 3 (7.3%) 14 (34.1%) 24 (58.5%)
Tumor size Not significant
pT1(a,b,c) 7 (7.2%) 21 (21.6%) 69 (71.1%)
pT2 5 (7.9%) 9 (14.3%) 49 (77.8%)
pT3 and pT4 1 (50%) 1 (50%)
* P value of chi-squared analysis.
Table 2
Primary antibodies used for immunohistochemistry
Antibody Dilution Source
Phospho-Akt (1/2/3) Serin 473 Polyclonal 1:200 Cell Signaling Technology
Phospho-Akt (1/2/3) Serin 473 Polyclonal 1:2000 Santa Cruz Biotechnology
Focal adhesion kinase (C-20) Polyclonal 1:100 Santa Cruz Biotechnology
Phospho-focal adhesion kinase tyrosine 861 Polyclonal 1:50 Santa Cruz Biotechnology
Phospho-Src tyrosine 215 Polyclonal 1:200 Sigma-Aldrich
Phospho-Src tyrosine 416 Polyclonal 1:200 Cell Signaling Technology
Phospho p44/42 Map kinase (Erk1/2) threonine 202;tyrosine 204 Monoclonal 1:100 Cell Signaling Technology
Estrogen receptor Monoclonal 1:25 DAKO
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ples with a readily detectable membranous staining or with
a strong cytoplasmatic staining were classified as positive.
Samples lacking or with a weak membranous staining or
with a weak cytoplasmatic staining were classified as
negative.
HER2 protein and ER status
The Her-2/neu status was determined according to the
evaluation system of the HerceptTest™. For statistical anal-
ysis, negative (DAKO score 0 and 1+) and positive (DAKO
score 2+ and 3+) groups were created. A tumor was
regarded as ER-negative if none or less than 10% of the
tumor cells showed weak or missing nuclear
immunostaining.
Western blot analysis
Total cell protein of seven representative frozen human
breast cancer samples was extracted in lysis buffer and the
protein concentration was measured to load equal protein
amounts. Each lane consisted of 50 µg protein, and was
size fractioned by electrophoresis on 10% polyacrylamide-
SDS gels and electrotransferred to a polyvinylidene
fluoride membrane using a tank-blotting system. After stain-
ing the membranes with reversible Ponceau red solution to
confirm equal protein loading, the membranes were
blocked with 5% non-fat dry milk in Tris-buffered saline for
1 hour at room temperature. The membranes were then
incubated with the anti-HER2/ErbB2 antibody (polyclonal
rabbit HER2/erbB2 antibody, 1:1000; Cell Signaling Tech-
nology, Inc.), anti-phospho-FAK antibody (Tyr-861, polyclo-
nal goat antibody, 1:50; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) and anti-phospho-Src antibody (Tyr
215, polyclonal rabbit antibody, 1:2000; Sigma-Aldrich,
Inc., St Louis, MO, USA) for 16 hours at room temperature.
After incubating the membrane for 1 hour with goat anti-
rabbit/donkey anti-goat antibody conjugated to horserad-
ish peroxidase, the antigen–antibody complex was visual-
ized by chemiluminescence (Amersham Biosciences,
Piscataway, NJ, USA).
Statistical analysis
FAK, phospho-Erk1/2, Her-2/neu, phosph-Src Tyr-215/
416 and ER immunostainings were assessed by a set of
pathologists (KJS, FG, JWO, FO) in a blind-trial fashion
without knowledge of the clinical outcome. In cases of dis-
agreement, the slides were evaluated by two pathologists
and a final decision was made. Two of the authors
assessed the percentage of phospho-AKT-positive tumor
cells and the mean percentage of both counts was used for
statistical analysis. Staining scores of both phospho-Akt
antibodies (Santa Cruz Biotechnology Inc. and Cell Signal-
ing Technology Inc.) revealed a high, significant interob-
server concordance (Pearson's r = 0.671, P < 0.001).
Results obtained from phospho-Akt immunostaining per-
formed with the antibody from Santa Cruz showed less
background staining, and were therefore used for statistical
analysis. All data were converted to a PC and statistically
analyzed using SPSS Version 10 for Windows (SPSS Inc.,
Chicago, IL, USA). Relationships between ordinal parame-
ters were investigated using two-tailed chi-squared analy-
sis (or Fisher's exact test where patient numbers were
small). The relationship between FAK expression and the
percentage of phospho-Akt-positive tumor cells was deter-
mined using the Kruskal–Wallis test. Overall survival curves
were estimated using the Kaplan–Meier method, and any
differences in the survival curves were compared by the
log-rank test. Western blot results were digitized with
Image Master software from Amersham Biosciences.
Results
Immunohistochemical analysis of FAK
Staining results were obtained from all 162 cases. In nor-
mal breast epithelium, a weak to missing FAK expression
Figure 1
Immunohistochemistry for focal adhesion kinase (FAK) in ductal carci-no a in situ, invas ve breast carcinonoma a d normal breast issue
noma in situ, invasive breast carcinonoma and normal breast tissue. (a) 
Strongest FAK expression was frequently seen in ductal carcinoma in 
situ (arrowhead). Notice the missing staining in normal breast tissue 
(arrow). (b) Invasive breast carcinoma cases (arrowhead) exhibited an 
equal or less intense FAK immunostaining then adjacent ductal carci-
noma in situ (arrow) in all but one case. Original magnification, × 400.
Figure 2
Representative immunohistochemical staining of a Her-2/neu and focal adhesion kinase (FAK)-overexpressing umor f r phospho-Src Tyr-215 nd ph spho-Src Tyr-416
adhesion kinase (FAK)-overexpressing tumor for phospho-Src Tyr-215 
and phospho-Src Tyr-416. Light micrograph displaying (a) strong 
phospho-Src Tyr-215 and (b) missing phospho-Src Tyr-416 staining in 
serial sections of a Her-2/neu-overexpressing and FAK-overexpressing 
invasive breast cancer sample as analyzed by immunohistochemistry. 
Inset: immunohistochemical staining showing FAK overexpression of 
the same sample. Original magnification, × 400.
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Strong FAK overexpression was detected in 30 patients
(18.5%), intermediate staining in 119 patients (73.5%) and
negative staining in 13 patients (8%). Higher FAK expres-
sion was significantly associated with a poorer differentia-
tion grade. No statistically significant differences were
found among cases with different tumor sizes or different
tumor types (Table 1). The staining intensity of an adjacent
in situ component was equal to or stronger than that of the
invasive tumor, with only one sample exhibiting a weaker
FAK staining in the in situ component than in the corre-
sponding invasive carcinoma (Fig. 1).
Correlation between FAK expression and survival
The impact of FAK expression and clinicopathological fea-
tures on patient survival was assessed using univariate
Kaplan–Meier survival analysis. Except for histological
grading (P = 0.005), ER status (P = 0.0033) and activation
of Akt (P = 0.0383), none of the other investigated param-
eters – including FAK expression (irrespective of ER
expression) or HER-2/neu status – proved to be of prog-
nostic significance in the node-negative breast cancers
examined.
Correlation of FAK protein expression with HER-2/neu 
status, ER status and phospho-Src Tyr-215 and phospho-
Src Tyr-416 overexpression
A total of 159 tumors were analyzed for HER-2/neu protein
expression: 59 tumors (37.1%) were classified as negative
(0), 56 tumors (35.2%) as negative (1+), 21 tumors
(13.2%) as weakly positive (2+) and 23 tumors (14.5%) as
strongly positive (3+). Tumors with a score of 2+ and 3+
were defined as Her-2/neu-positive. A total 51.7% of
tumors classified as strongly FAK-positive exhibited Her-2/
neu protein overexpression, but intermediate classified
tumors totaled only 24.5% of Her-2/neu overexpressing
tumors. All of the FAK-negative tumors were Her-2/neu-
negative. The ER status was obtained from 152 tumors.
Ninety tumors (59.2%) showed a significant ER expression
whereas 62 tumors (40.8%) were classified as negative.
Statistical analysis revealed a significant relationship of ele-
vated FAK expression (P = 0.001) with Her-2/neu overex-
pression (2+ and 3+; Table 3) but not with the ER status.
Phospho-Src Tyr-215 staining was obtained from 137
patients and phospho-Src Tyr-416 staining was obtained
from 140 samples. Normal breast tissue exhibited no phos-
pho-Src Tyr-215 immunostaining. Membranous phospho-
Figure 3
Representative immunohistochemical staining of serial sections of three tumors for phospho-Akt, focal adhesion kinase (FAK) and HER2i l ti  f t r  t rs f r phospho- kt, focal adhesion kinase (FAK) and HER2. (A1)–(A3) 
HER2: tumors with strong HER2 staining intensity (DAKO score 3+) (A1), weak HER2 staining (DAKO score 1+) (A2) and missing HER2 staining 
(DAKO score 0) (A3). (B1)–(B3) Tumors showing strong HER2 immunostaining (A1) more frequently exhibited strong FAK immunostaining (B1), 
whereas tumors expressing weak or no HER2 immunostaining were more often associated with weak or no FAK immunostaining (B2, B3). (C1)–
(C3) Phospho-Akt: the percentage of phospho-Akt positively stained tumor cells ranged from more than 80% (C1) to 45% (C2) or was lower than 
45% (C3). Higher HER2 (A1) and FAK (B1) staining intensites are correlated with higher percentage of phospho-Akt positively stained tumor cells 
(C1, C2). Original magnification, × 200.
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thelial cells. Myoepithelial cells lacked both phospho-Src
Tyr-215 and phospho-Src Tyr-416 immunostaining. Tumor
tissue of the remaining samples was not available due to
lack of paraffin material. Statistical analysis revealed a sig-
nificant direct correlation of FAK overexpression with phos-
pho-Src Tyr-215 staining results (P = 0.021) but not with
phospho-Src Tyr-416 staining scores (Table 3). On the
other hand, positive phospho-Src Tyr-215 staining was sig-
nificantly associated with HER2 overexpression (P =
0.011) whereas phospho-Src Tyr-416 was not. Represent-
ative immunohistochemical stainings are shown in Figs 2
and 3.
Correlation between FAK expression and Akt/ERK 
activation
Normal breast tissue revealed mostly a cytoplasmatic Akt-
staining pattern, with a low mean percentage of positive
nuclear stained cells in normal breast tissue of 28%. Prom-
inent nuclear and partly cytoplasmatic phospho-Akt immu-
noreactivity was noticed in tumor cells. Staining
heterogeneity was occasionally apparent at the invasive
tumor front. The percentage of phospho-AKT-positive
nuclei in the tumor samples ranged from 0% to 85%.
Tumors with more than 45% of positive nuclei were classi-
fied as phospho-Akt-positive.
Erk1/2 immunohistochemistry of tumor samples revealed
strong nuclear immunostaining and partly cytoplasmatic
immunostaining, while non-neoplastic tissue only occasion-
ally revealed a weak staining. Similar to phospho-Akt, het-
erogeneous immunostaining for phospho-ERK1/2 was
detected at the invasive tumor front. Phospho-Akt-positive
classified tumors exhibited stronger FAK immunostaining
intensities more frequently (P < 0.001) than phospho-Akt-
negative classified tumors.
No correlation was observed between different FAK immu-
nostaining scores and phospho-ERK1/2 immunostaining
scores (P = 0.108) (Table 3). Statistical analysis revealed
a significant direct correlation of different FAK
Table 3
Correlation between focal adhesion kinase, HER2, estrogen receptor, phospho-Src Tyr-215 and phospho-Src Tyr-416, phospho-Akt 
and phospho-ERK1/2 immunohistochemistry
Focal adhesion kinase expression P value*
Negative Intermediate Strong
Her-2/neu status (n = 159) 0.001
Negative (0, 1+) 13 88 14
Positive (2+, 3+) 0 29 15
Estrogen receptor status (n = 152) Not significant
Negative 4 48 10
Positive 6 67 17
Phospho-Src Tyr-215 (n = 137) 0.021
Negative 9 87 17
Positive 15 9
Phospho-Src Tyr-416 (n = 140) Not significant
Negative 8 86 21
Positive 20 5
Phospho-Akta (n = 162) < 0.001
Negative 7 10 1
Positive 6 109 29
Phospho-ERK1/2 (n = 161) Not significant
Negative 5 28 9
Intermediate 8 74 13
Strong 16 8
* P value of chi-squared analysis.
aNegative, percentage of phospho-Akt-positive cells ≤ 45%; positive, percentage of phospho-Akt-positive cells > 45%.
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pho-Akt-positive stained tumor cells (P < 0.001).
Correlation between HER2 protein overexpression and 
phosphorylation of FAK at Tyr-861 in western blot 
analysis
We next analyzed the relationship of HER2 overexpression
with the levels of phospho-Src Tyr-215, phospho-FAK Tyr-
861 and total FAK using seven samples of fresh-frozen
breast cancer tissue. Of the seven samples analyzed, four
tumors with high HER2 levels exhibited increased levels of
phosphorylation of FAK on tyrosine 861 compared with
tumors without HER2 overexpression (P = 0.01; Fig. 4). An
increase of total FAK and phospho-Src Tyr-215 was
noticed within the HER2 overexpressing tumors but
reached not statistical significance. These results provide
evidence that the HER/FAK Tyr-861 pathway is activated in
human breast cancer.
Discussion
Several studies have demonstrated upregulation of FAK
expression in malignant tumors, including breast cancer,
but the prognostic value of FAK expression in human
cancer remains unclear. From the three studies that have
previously analyzed this, one study denies the prognostic
value of FAK in adenocarcinomas of the colon [16],
whereas the other two studies have provided evidence for
the prognostic value of immunohistochemically detected
FAK expression in esophageal squamous carcinoma and in
hepatocellular carcinoma, respectively [15,17]. The
present study is the first to clarify the prognostic relevance
of FAK expression in a cohort of 162 invasive node-nega-
tive breast cancer cases with long-term follow-up. Our find-
ings demonstrate that FAK overexpression does not
predict patient outcome in this setting; although, similar to
esophageal squamous cancers, levels of FAK expression
were strongly correlated with poorer tumor differentiation
[17].
FAK is a nonreceptor protein kinase involved in integrin-
mediated signaling that has a profound impact on cell
proliferation, survival and migration. One downstream tar-
get is the PI3K/Akt signaling pathway. In the present study
we found a significant association of elevated FAK expres-
sion with Akt phosphorylation in support of the notion that
Akt may be a downstream target of FAK-mediated signaling
[27]. However, while Akt activation is associated with a
worse prognosis in our study cohort, FAK expression levels
are not. This may be due to the central role of Akt in tumor-
igenesis, where a number of stimuli and pathways besides
FAK contribute to the common end point of increased Akt
activity.
Akt, also known as protein kinase B, is a serine/threonine
protein kinase that has been shown to regulate cell survival
signals in response to a diversity of signals generated by
growth factors, cytokines and oncogenic ras. Alternative
activation mechanisms for Akt besides growth factor-medi-
ated PI3K stimulation are mutational inactivations of PTEN
or activation via integrin-linked kinase [28-30]. The differ-
ence in prognostic relevance between Akt and FAK may
therefore not be surprising. Several studies have demon-
strated upregulation of FAK in human cancer including
breast cancer and have suggested that FAK overexpres-
sion is an early event in tumorigenesis [13,14]. Our data
support this hypothesis as all (but one) of the in situ carci-
nomas adjacent to the invasive cancer exhibited FAK over-
expression. Interestingly, in every cancer specimen
analyzed the adjacent preinvasive component exhibited an
equal or even higher FAK immunostaining than the corre-
sponding invasive carcinoma.
In recent studies, Vadlamudi and colleagues utilized human
breast cancer cell lines in vitro to establish a novel signal-
ing pathway involving HER2, phospho-Src Tyr-215 and
phospho-FAK Tyr-861 leading to increased cellular motility
[18,19]. The authors showed that heregulin-induced HER2
activation resulted in phosphorylation of FAK at tyrosine
Figure 4
Upregulation of tyrosine phosphorylation of focal adhesion kinase (FAK) at tyrosine 861 in HER2-overexpressing breast tumors. Western blot analy-
sis: lysates of seven breast cancer samples were analyzed by immunoblotting using antibodies that recognize total FAK and distinct tyrosine sites on 
Src and FAK kinases. Tumor samples were put in order according to the HER2 expression status (HerceptTest™) and the blot was probed with anti-
HER2 antibody to analyze the exact amount of HER2 protein.
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level of phospho-Src Tyr-215 in HER2 neu-overexpressing
breast cancers. From these in vitro data it was tempting to
hypothesize that HER2 influences metastasis of breast
cancer in vivo via a similar pathway.
To test for the existence of this novel pathway in a large
cohort of human breast cancer tissue we evaluated total
FAK protein and phospho-Src Tyr-215 expression as well
as phospho-Src Tyr-416 expression by immunohistochem-
istry. Additionally, we investigated the levels of phospho-
FAK Tyr-861, phospho-Src Tyr-215 and Her-2/neu in a set
of seven of freshly frozen breast cancer tissues using west-
ern blot analysis. Our findings support the hypothesis that
HER2-overexpressing tumors exhibit higher levels of phos-
pho-FAK Tyr-861 but also of total FAK levels. This is also
supported by the immunohistochemical data where Her-2/
neu protein expression levels coincide with FAK protein
expression. Interestingly, increased levels of phospho-Src
Tyr-215 but not of phospho-Src Tyr-416 were significantly
associated with HER2 overexpression, supporting the role
of an activatory Src Tyr-215 phosphorylation as an interme-
diate between HER2 and FAK signaling.
Although Src comprises several phosphorylation sites,
phosphorylation of tyrosine 215 and not tyrosine 416, the
'classical' activatory phosphorylation site, appears to be
essential for FAK activation via HER2 [19]. Our data con-
firm the specificity of this pathway as src phosphorylation
at tyrosine 416 was not associated neither with HER2 over-
expression. The present study was designed to investigate
this novel signaling pathway in vivo via an
immunohistochemical approach allowing the determination
of HER2 and FAK protein expression.
A recent study identified frequent polysomic patterns for
chromosome 1, chromosome 8 and chromosome 17 that
are indicative for increased tumor malignancy in breast can-
cer [31]. As the focal adhesion kinase and the Her-2/neu
gene are located on chromosome 8 and chromosome 17,
respectively, one might conclude that such a polysomic
pattern causes a combined HER2/FAK protein overexpres-
sion. However, the identification of potential underlying
causative genetic alterations should be a topic of further
investigation.
Our results propose that among the many biological effects
of Her-2/neu overexpression the activation of the Akt sur-
vival pathway via the FAK Tyr-861–Src Tyr-215 pathway
might contribute to the more aggressive behavior of Her-2/
neu-overexpressing breast cancers.
In summary, FAK overexpression is not a prognostic marker
in this series of 162 node-negative breast cancers. This
might be due to the composition of our cohort, which
mainly contains early-stage cancers without lymph node
metastasis. Recent studies demonstrated a higher level of
FAK expression in colorectal liver metastasis than in the pri-
mary tumor, and provided evidence for an upregulation of
FAK protein in hepatocellular cancers with portal invasion
Figure 5
Scheme depicting signalling transduction in breast cancer involving HER2, Src, focal adhesion kinase (FAK), phosphatidylinositol 3-kinase (PI3K), Akt and Erk
Akt and Erk.
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with Her-2/neu overexpression and may mediate HER2 sig-
naling via Src, resulting in PI3K/Akt activation. These data
might contribute to the understanding of how Her-2/neu
overexpression in human breast cancer affects tumor
malignancy and metastasis (Fig. 5). Owing to the relatively
small number of breast cancer samples exhibiting FAK pro-
tein overexpression in this cohort, however, these promis-
ing results need to be confirmed in larger cohorts.
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